<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01102205</url>
  </required_header>
  <id_info>
    <org_study_id>tastoshashi</org_study_id>
    <nct_id>NCT01102205</nct_id>
  </id_info>
  <brief_title>Evaluation of Oxidative Stress and Effect of Levothyroxine Treatment on Oxidative Stress in Hashimoto Disease</brief_title>
  <official_title>Evaluation of Oxidative Stress and Effect of Levothyroxine Treatment on Oxidative Stress in Hashimoto Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vakif Gureba Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vakif Gureba Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oxidative stress leads to or accompanies with numerous disease. Oxidative balance in
      subclinical hypothyroid or euthyroid state in Hashimoto disease are not known. Effect of
      levothyroxine therapy on oxidative balance are also not known in hashimoto disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      oxidative stress markers will be measured initially(TAS,TOS,OSI,PARAOXONASE,ARYLESTERASA,PON1
      PHENOTYPİNG,LİPİDPEROXİD).After 3 months therapy with levothyroxine measurements will be
      repeated except PON1 phenotyping.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Poxidative stress markers</measure>
    <time_frame>After levotren therapy</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">130</enrollment>
  <condition>Hashimoto Disease</condition>
  <arm_group>
    <arm_group_label>healthy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>euthyroid hashimoto</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>hypothyroid hashimoto</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      after overnight fasting state,venous blood will be taken to obtain serum.speciemens stored
      -70 cantigrade celcius untillanalysing.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        adult with Hashimoto disease in euthyroid or subclinical hypothyroid state and healthy
        control.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age more than 18 years

        Exclusion Criteria:

          -  inability to give a written consent

          -  other conditions and drug usage affect oxidative stress
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehmet ali Cikrikcioglu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>vakif gureba TRH,fatih,istanbul,turkey.specialist in internal medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vakif Gureba Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2010</study_first_submitted>
  <study_first_submitted_qc>April 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2010</study_first_posted>
  <last_update_submitted>June 11, 2013</last_update_submitted>
  <last_update_submitted_qc>June 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vakif Gureba Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>Mehmet Ali Cikrikcioglu</investigator_full_name>
    <investigator_title>Vakif Gureba TRH</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hashimoto Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

